Literature DB >> 6969364

Elastolytic activity in pulmonary lavage fluid from patients with adult respiratory-distress syndrome.

C T Lee, A M Fein, M Lippmann, H Holtzman, P Kimbel, G Weinbaum.   

Abstract

To test the hypothesis that adult respiratory-distress syndrome (ARDS) is related to increased activity of the proteolytic enzyme elastase released from neutrophils in the lung, we determined the differential white-cell count, the elastolytic activity, the source of elastase, and the concentration and activity of the endogenous protease inhibitor alpha-1-antiprotease (alpha-1-AP) in bronchoalveolar lavage fluid from 23 patients with ARDS and from 55 patients without this syndrome. Neutrophil predominance (> 80 per cent) was observed in 18 of 23 patients with ARDS. High elastolytic activity of neutrophil origin was found in 12 of 23 patients with ARDS (52 per cent), in none of 16 normal nonsmokers (P < 0.01), in two of 17 normal smokers, and in three of 22 patients with chronic obstructive pulmonary disease. Although there were no significant differences in alpha-1-AP concentrations, its activity was reduced in eight of nine patients with ARDS and high elastolytic activity. We conclude that in many patients with ARDS, high levels of neutrophil elastolytic activity in the lungs are associated with reduced alpha-1-AP function.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6969364     DOI: 10.1056/NEJM198101223040402

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  88 in total

Review 1.  The pulmonary physician in critical care * 6: The pathogenesis of ALI/ARDS.

Authors:  G J Bellingan
Journal:  Thorax       Date:  2002-06       Impact factor: 9.139

Review 2.  The pulmonary physician and critical care. 3. Pharmacotherapy in lung injury.

Authors:  M Messent; M J Griffiths
Journal:  Thorax       Date:  1992-08       Impact factor: 9.139

3.  An increase in plasma concentrations of granulocyte elastase during and after bench surgery of the liver.

Authors:  K Irita; T Taniyama; H Okamoto; H Inoue; M Umeki; S Inaba; S Taniguchi; Y Sakaguchi; K Mazuda; M Yamakawa; J Yoshitake; S Takahashi
Journal:  J Anesth       Date:  1993-07       Impact factor: 2.078

Review 4.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 5.  Exogenous surfactant treatments for neonatal respiratory distress syndrome and their potential role in the adult respiratory distress syndrome.

Authors:  T A Merritt; M Hallman; R Spragg; G P Heldt; N Gilliard
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

6.  Effects of neutrophil elastase inhibitor on progression of acute lung injury following esophagectomy.

Authors:  Satoshi Ono; Hironori Tsujimoto; Shu-Ichi Hiraki; Risa Takahata; Akifumi Kimura; Manabu Kinoshita; Takashi Ichikura; Hidetaka Mochizuki
Journal:  World J Surg       Date:  2007-10       Impact factor: 3.352

7.  Cellular mechanisms of acute lung injury: implications for future treatment in the adult respiratory distress syndrome.

Authors:  S C Donnelly; C Haslett
Journal:  Thorax       Date:  1992-04       Impact factor: 9.139

8.  Activation of polymorphonuclear leukocytes in oleic acid-induced lung injury.

Authors:  H Moriuchi; M Zaha; T Fukumoto; T Yuizono
Journal:  Intensive Care Med       Date:  1998-07       Impact factor: 17.440

9.  Activity of lung neutrophils and matrix metalloproteinases in cyclophosphamide-treated mice with experimental sepsis.

Authors:  Mark Hirsh; Julie Carmel; Viktoria Kaplan; Erella Livne; Michael M Krausz
Journal:  Int J Exp Pathol       Date:  2004-06       Impact factor: 1.925

10.  A genome-wide expression analysis in blood identifies pre-elafin as a biomarker in ARDS.

Authors:  Zhaoxi Wang; Douglas Beach; Li Su; Rihong Zhai; David C Christiani
Journal:  Am J Respir Cell Mol Biol       Date:  2008-01-18       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.